All three drugs dampen appetite by affecting the patient's central nervous system, according to Charles Billington, a professor of medicine at the University of Minnesota and
medical director of the obesity program at the Minneapolis VA Medical Center. "To say that you are going to do that without any side effects is just not understanding how things work in real life," he
says.
The three new drugs are Arena Pharmaceutical's Lorcaserin, Vivus' Qnexa, and Orexigen Therapeutic's Contrave. Each company has held talks with a larger concern to help sell the products but no agreements have been signed, Gryta writes.
advertisement
advertisement